Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference
November 04, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the company’s...
Kura Oncology to Participate in Two Upcoming Investor Conferences
November 01, 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and...
Kura Oncology to Report Third Quarter 2016 Financial Results
October 31, 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the 9th European Scientific Oncology Conference
October 31, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 9th European...
Kura Oncology to Participate in the 2016 Aegis Growth Conference
September 14, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth...
Kura Oncology to Participate in the 5th Annual Gateway Conference
September 02, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway...
Kura Oncology Reports Second Quarter 2016 Financial Results
August 10, 2016 16:03 ET
|
Kura Oncology, Inc.
Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host webcast and conference call today at...
Kura Oncology to Report Second Quarter 2016 Financial Results
August 03, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial...
Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results
March 17, 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company, today announced highlights and financial results for the fourth...
Kura Oncology to Report Fourth Quarter and Full Year 2015 Financial Results
March 11, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that it will report fourth quarter and full year...